Skip to main content

Table 5 Association between VL Testing and Second-Line Regimen Switching (n = 66,042)a

From: Expanded access to viral load testing and use of second line regimens in Haiti: time trends from 2010–2017

 NHR95% CIp-value
VL test statusNo test36,4421.0Ref.Ref.
Suppressed19,8290.4(0.3, 0.5)< 0.001
Unsuppressed60225.6(4.9, 6.5)< 0.001
Re-suppressed13282.3(1.3, 4.4)< 0.01
Confirmed failure242122.2(18.8, 26.3)< 0.001
Age group16~2481731.0Ref.Ref.
25~3422,3351.0(0.9, 1.2)0.89
35~4418,8280.9(0.8, 1.1)0.45
45~5410,7780.8(0.7, 1.0)0.09
> 5559280.7(0.6, 0.9)< 0.01
GenderFemale42,6231.0Ref.Ref.
Male23,4191.4(1.2, 1.5)< 0.001
Baseline WHO stageStage 112,8791.0Ref.Ref.
Stage 210,9831.4(1.1, 1.8)< 0.01
Stage 314,2171.9(1.6, 2.4)< 0.001
Stage 421,8143.2(2.6, 3.9)< 0.001
Missing61491.4(1.1, 1.9)0.01
Year of ART initiation2010–201218,4181.0Ref.Ref.
201310,8120.7(0.6, 0.8)< 0.001
201411,6290.6(0.5, 0.7)< 0.001
201510,4830.8(0.6, 0.9)< 0.01
2016–201714,7000.5(0.4, 0.7)< 0.001
  1. aIncludes all ART patients (see Table 1 for characteristics of 66,042 ART patients)